Home › Breast Cancer › Wisconsin › Madison
Breast Cancer clinical trials in Madison, WI
22 studies for Breast Cancer are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RecruitingPhase 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RecruitingPhase 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RecruitingPhase 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RecruitingPhase 3
- University of Wisconsin-Madison ( Site 0024), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Recruiting
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RecruitingPhase 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
RecruitingPhase 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
RecruitingPhase 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
RecruitingPhase 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RecruitingPhase 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RecruitingPhase 1
- UW Carbone Cancer Center, Madison
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY136 studies
- Houston, TX126 studies
- Boston, MA112 studies
- Nashville, TN81 studies
- Los Angeles, CA73 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Queens, NY64 studies
- Durham, NC64 studies
- Chicago, IL59 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer23 studies
- Metastatic Cancer21 studies
- Acute Myeloid Leukemia16 studies
- Non-Small Cell Lung Cancer16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Pancreatic Cancer10 studies
- Lung Cancer10 studies
- Multiple Myeloma9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.